Aquila Bioscience

Aquila Bioscience is based in the heart of the medical device technology sector in Galway Ireland.

Aquila was founded in 2012 at the National University of Ireland, Galway, by Lokesh Joshi, Stokes Professor of Glycoscience. We have developed revolutionary decontamination technology in collaboration with the Czech University of Defence and Defence Forces Ireland, that protects against harmful pathogens and other viral infections like coronavirus.

We have successfully applied this technology and launched the first Aquila Bioscience product, “ABD Device”. It is free from alcohol and toxic chemicals, and is a biodegradable Class I device that safely captures, removes and neutralizes harmful pathogens and viral infections like coronavirus from the skin and surfaces.

Our experienced R&D team bring together a range of science disciplines, bridging Glycobiology, Immunology, Microbiology, biochemistry and analytical chemistry.

Connecting
Science & Nature

Our Mission

Using nature’s solutions to develop technologically-advanced and environmentally-friendly products to improve the world’s health

Our Values

Respect / Sustainability​: Have a deep respect for each other and the world we live in
Integrity: Always try to do the right thing
Excellence​: Strive to be the best we can possibly be

History

Aquila Bioscience is selected for EIC Accelerator Funding
April 2020
1st ABD produced by Aquila
March 2020
European Union SME-Phase 2 Application in process to develop ABD technology
May 2019
European Union SME-Phase 1 award to develop Glyco-DeCon technology
2016-2020 (ongoing)
European Defence Agency for decontaminating bacteria and bacterial toxins
2013
Founded
Founded by Lokesh Joshi in the National University of Ireland, Galway (NUIG)
June 2020
Anti Bioagent Device Image
1st ABD delivered to customer
March 2020
CEO & Aquila team appointed
2020
UK Patent filed-Device and Method for Decontamination / disinfection
2017
Partnership in PATHSENSE ITN focused on foodborne pathogens
2015
European Union project on bacterial detection in water
2012
Aquila Bioscience is selected for EIC Accelerator Funding
Anti Bioagent Device Image
1st ABD delivered to customer
1st ABD produced by Aquila
CEO & Aquila team appointed
European Union SME-Phase 2 Application in process to develop ABD technology
UK Patent filed-Device and Method for Decontamination / disinfection
European Union SME-Phase 1 award to develop Glyco-DeCon technology
Partnership in PATHSENSE ITN focused on foodborne pathogens
European Defence Agency for decontaminating bacteria and bacterial toxins
European Union project on bacterial detection in water
Founded
Founded by Lokesh Joshi in the National University of Ireland, Galway (NUIG)
April 2020
March 2020
March 2020
2020
May 2019
2017
2016-2020 (ongoing)
2015
2013
2012

Our Team

 

Science Team

Prof. Lokesh Joshi – Founder
Dr. Marta Utratna – R&D
Dr. Anup Mammen – R&D

Dr Ciarán Duffy – Research and Innovation Funding

Cormac Lynch – CEO

Commercial Team

Fran O’Flaherty – Commercialisation
Lorraine Eagleton – Sales & Marketing
Sean Mannion – Manufacturing
John Martyn – Regulatory

 

Services Team

Niall Mooney – Finance
Gillian Knight – Human Resources

Learn how our ABD Device can protect you from pathogens and other viral infections like CORONAVIRUS

Registered for sale in the USA and available in Europe

Anti Bioagent Device Image